The BMJ analysis used electronic health records to compare adults who initiated tirzepatide with those who initiated sitagliptin, tracking major adverse cardiovascular events — heart attack, stroke, and death from any cause. The absolute numbers were small on both sides, which is normal for a one-year horizon, but the difference was consistent with the randomized trial evidence: tirzepatide users had roughly one-third fewer heart attacks, and the analysis estimated one cardiovascular event prevented for every 70 patients treated over a year. The researchers described the work as trial-anchored real-world evidence, meaning it checks whether trial benefits actually appear when the drug is used in ordinary clinics.
Two caveats belong next to those numbers. The study is observational, so it compares users of the two drugs rather than randomly assigning them, and the population is specific — adults with type 2 diabetes and established cardiovascular disease. The result does not mean the drug is risk-free; it means the cardiovascular benefit seen in trials is visible in practice.
For a stone patient, the relevant question is not whether GLP-1 therapy reduces heart attacks — it is what the therapy does to the eating pattern that determines stone chemistry. Appetite suppression is the mechanism that drives weight loss, and it is also the mechanism that can quietly remove dairy and fluid from the day. When appetite shrinks, calcium intake often falls with it, and low dietary calcium is a well-documented risk factor for oxalate stone formation. Fluid intake can drop too, because thirst signals blur when hunger is suppressed, and concentrated urine is the single most consistent stone risk.
Rapid weight loss adds a third variable. Fast weight change has been associated in the stone literature with shifts in urine chemistry, including transient uric acid changes, which is why stone specialists often want a urine test both before and after weight loss begins. None of this argues against the medication — it argues for running the medication inside a measured dietary structure.
The stone-aware pattern for GLP-1 therapy is small, frequent, calcium-first eating. Because appetite is limited, every bite should carry calcium or protein: Greek yogurt, milk, string cheese, cottage cheese, a small chicken or egg salad with cheese. Water goes on a schedule independent of thirst — a bottle at each meal plus refills between, enough to keep urine pale. High-oxalate foods stay measured rather than eliminated, and the 24-hour urine test calibrates the plan before the drug starts and again after weight stabilizes.
| Food | Oxalate (mg) | Serving | Rating |
|---|---|---|---|
| Greek yogurt, plain | 0 | 1 cup | Safe |
| Milk, cow's | 0 | 1 cup | Safe |
| String cheese | 0 | 1 oz | Safe |
| Cottage cheese | 0 | 1/2 cup | Safe |
| Chicken breast, roasted | 0 | 4 oz | Safe |
| Tofu, firm | 10 | 1/2 cup | Safe |
| Broccoli, boiled | 4 | 1/2 cup | Safe |
The cardiovascular evidence makes GLP-1 therapy more likely to be continued long-term, which makes the follow-up rhythm more important. A practical schedule: a 24-hour urine collection before starting or early in treatment; a repeat after weight stabilizes or after any dose change; and kidney function markers on the same schedule. The urine test shows whether the calcium-first plan is actually protecting citrate and calcium balance, or whether the medication's appetite effect is quietly undoing it. The patient who treats the medication and the diet as one system gets the weight and cardiovascular benefit without trading away kidney protection.
Not directly, but the eating changes it causes can. Appetite suppression can reduce calcium and fluid intake, and rapid weight loss has been associated with urine chemistry shifts in some research. The measured version keeps dairy and water on schedule through the weight-loss process.
Dairy first, in small portions: Greek yogurt, milk, string cheese, cottage cheese. These deliver 200-400 mg of calcium at zero oxalate, and dairy before other foods protects the calcium line even when only part of a meal is eaten.
Set a schedule rather than relying on thirst, because appetite suppression can blur thirst signals. A practical target is a glass at each meal plus refills between, enough to keep urine pale through the day.
The real-world data strengthen the case for continuing GLP-1 therapy, which makes the ongoing dietary structure more important rather than less. A patient who stays on the medication for years will manage appetite suppression for years, and the dairy-first, water-on-schedule pattern is a long-term structure, not a short-term fix. The conversation with the care team should cover the stone variables explicitly: the stone type if one has formed, the baseline urine chemistry, and the follow-up rhythm for repeat testing. The medication is a tool the diet operates inside — and the diet is the part the patient controls.
See how oxalate values are measured and verified on our data methodology page.